Spexis AG / Key word(s): Research UpdateSpexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model 07.07.2022 / 07:30 Allschwil, Switzerland, July 7, 2022Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic eff.